Develops therapies to treat inflammatory diseases, viral infections, and cancer by modulating the body's immune system.
ABIVAX Societe Anonyme is a dynamic clinical-stage biotechnology company headquartered in Paris, France, dedicated to pioneering therapies that harness the body's innate regulatory mechanisms to manage and stabilize immune responses in patients battling chronic inflammatory diseases. Since its inception in 2013, ABIVAX has been at the forefront of biopharmaceutical innovation, focusing on developing groundbreaking treatments that address significant unmet medical needs.
Central to ABIVAX's pipeline is obefazimod, the company's lead drug candidate currently advancing through Phase 3 clinical trials. Obefazimod represents a promising therapeutic approach for the treatment of moderately to severely active ulcerative colitis in adults. By targeting the mechanisms underlying immune dysregulation, obefazimod aims to provide effective relief and improve the long-term outcomes for patients suffering from this debilitating condition.
In addition to its pioneering research in ulcerative colitis, ABIVAX continues to explore the therapeutic potential of its platform across a spectrum of chronic inflammatory diseases. The company's comprehensive approach integrates cutting-edge science with a deep commitment to patient welfare, driving its efforts to redefine standards of care and bring transformative therapies to market. With a robust scientific foundation and strategic partnerships, ABIVAX is poised to make a lasting impact in the field of biotechnology, offering hope to patients and clinicians alike in their quest for effective treatments.